Short answer
Bristol Myers Squibb (BMY) filed its Q3 2026 10-Q quarterly report on Oct 29, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $13.1B (up 6.9% year over year) with net income of $2.2B.
Q3 2026 key financials · XBRL
- Revenue
- $13.1B
- +6.9% YoY · +0.7% QoQ
- Net income
- $2.2B
- −1.8% YoY · −34.8% QoQ
- EPS (diluted)
- $1.05
- −2.8% YoY · −35.2% QoQ
Source: XBRL data from the Bristol Myers Squibb (BMY) Q3 2026 10-Q on SEC EDGAR. USD.
Bristol Myers Squibb Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $13,069 million, up 7% YoY from $12,222 million
- Effective tax rate 14.8% vs 29.5% YoY, non-GAAP EPS $1.35 vs $1.63
- Best product: Eliquis revenue $4,690 million, up 25% YoY; worst: Pomalyst/Imnovid, down 81%
- Operating cash flow $8.7 billion year-to-date vs $12.2 billion, net debt improved to $29.9 billion
- Headwinds: generic erosion, Eliquis price reduction, IRA pricing pressure, and potential further government price negotiations
Risk Factors
- No material changes from the risk factors disclosed in the 2025 Form 10-K
- Carried-forward risks include pharmaceutical regulatory approval and compliance exposure
- Carried-forward risks include product development and clinical trial uncertainty
- Carried-forward risks include competition and market pressures
- Carried-forward risks include liquidity, debt, and foreign currency exposures
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Bristol Myers Squibb quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.